Corbus Pharmaceuticals reported a net loss of $95.8 million for the nine months ended September 30, 2026, driven by a significant increase in research and development expenses related to its ADC and obesity pipelines. The company's cash and investment position decreased to approximately $115.3 million from $163.3 million at the end of 2025, despite raising $27.6 million through common stock issuances.
Corbus Pharmaceuticals reported Q3 2026 financial results and provided updates on its clinical pipeline, including the initiation of the TEMPO-1 registrational study for sutantatug envedotin in oropharyngeal cancer. The company also reported positive topline data from its CANYON-1 Phase 1b obesity study, showing 5% mean weight loss at 12 weeks for its CB1 inverse agonist CRB-913. Corbus ended the quarter with $145.6 million in cash and cash equivalents, providing a projected runway into Q3 2027.
“The commencement of the TEMPO-1 trial marks our transition to late-stage clinical development, bringing us meaningfully closer to delivering sutantatug envedotin as a potentially novel, targeted therapeutic for those impacted by OPSCC who were previously treated with platinum-based and anti-PD1 therapy.”
Yuval Cohen, Ph.D., Chief Executive Officer of Corbus
“For CRB-913, our topline CANYON-1 data demonstrated, for the first time, that a highly peripherally restricted CB1 inverse agonist can deliver a safe and tolerable therapeutic alternative with competitive weight loss to oral GLP-1s.”
Yuval Cohen, Ph.D., Chief Executive Officer of Corbus